$8.70−0.10 (−1.14%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
Teladoc Health (TDOC) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 1.5% in FY25, net margin −7.9%. Worth your attention in FY25: Share count (+12.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼1.5%
2,530.0
FY21→FY25CAGR +5.6%/yr
Net income ($M)▲80.0%
−200.3
one-off year: see footnoteCAGR —
Free cash flow ($M)▼1.6%
166.9
FY21→FY25CAGR +6.4%/yr
Diluted EPS▲80.6%
−1.14
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+12.3%
156.9mn → 176.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$127.5M
steady at 5.0% of revenue (+2.7% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-8¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 68.0% → 69.5%. Net margin -7.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 2,468.1 | 2,530.0 | 2,569.6 | 2,602.4 | 2,406.8 | 2,032.7 | ▼1.5% | +5.6% |
Cost of revenue | 775.7 | 771.6 | 751.3 | 760.0 | 744.0 | 650.3 | ▲2.7% | +4.4% |
Gross profit | 1,692.5 | 1,758.4 | 1,818.3 | 1,842.4 | 1,662.9 | 1,382.4 | ▼3.3% | +6.2% |
Research & development | 267.9 | 277.9 | 307.3 | 348.5 | 333.6 | 311.9 | ▼9.6% | −2.8% |
Selling, general & admin | 619.9 | 626.4 | 640.5 | 678.4 | 677.0 | 688.6 | ▼2.2% | −2.3% |
Total operating expenses | 1,855.4 | 2,021.3 | 2,839.2 | 2,090.9 | 15,316.1 | 1,648.1 | ▼28.8% | +5.2% |
Operating incomefeeds ROC rank | −163.0 | −263.0 | −1,020.9 | −248.6 | −13,653.2 | −265.6 | ▲74.2% | — |
Other income, net | 4.3 | 27.4 | 27.2 | 28.9 | −10.1 | −119.0 | — | — |
Pretax income | −158.7 | −235.5 | −993.7 | −219.6 | −13,663.3 | −384.7 | ▲76.3% | — |
Income tax | −3.8 | −35.2 | 7.6 | 0.8 | −3.8 | 44.1 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −154.8 | −200.3 | −1,001.2 | −220.4 | −13,659.5 | −428.8 | ▲80.0% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.86 | −1.14 | −5.87 | −1.34 | −84.60 | −2.73 | ▲80.6% | — |
Diluted shares (mn) | 181.88 | 176.22 | 170.56 | 164.58 | 161.46 | 156.94 | ▲3.3% | +2.9% |
| Margins | ||||||||
Gross margin53rd pct in Healthcare | 68.6% | 69.5% | 70.8% | 70.8% | 69.1% | 68.0% | ▼1.3pp | +1.5pp |
Operating margin | −6.6% | −10.4% | −39.7% | −9.6% | −567.3% | −13.1% | ▲29.3pp | +2.7pp |
Net margin30th pct in Healthcare | −6.3% | −7.9% | −39.0% | −8.5% | −567.5% | −21.1% | ▲31.0pp | +13.2pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was −11% vs a −0% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 15% vs a −0% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Teladoc Health's revenue last fiscal year?
Teladoc Health reported revenue of $2,530.0M in fiscal 2025, down 1.5% from fiscal 2024.
What was Teladoc Health's net income?
Teladoc Health reported net income of −$200.3M in fiscal 2025, a net margin of −7.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

